Development and optimization of PSCA-specific CAR T cells for the treatment of bone metastatic prostate cancer

Journal for ImmunoTherapy of Cancer, Nov 2015

Ethan Gerdts, Saul Priceman, Dileshni Tilakawardane, Anthony Park, Wen-Chung Chang, Sarah Wright, Christine E Brown, Stephen J Forman

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

http://www.immunotherapyofcancer.org/content/pdf/2051-1426-3-S2-P115.pdf

Development and optimization of PSCA-specific CAR T cells for the treatment of bone metastatic prostate cancer

Gerdts et al. Journal for ImmunoTherapy of Cancer Development and optimization of PSCA-specific CAR T cells for the treatment of bone metastatic prostate cancer Ethan Gerdts 1 2 Saul Priceman 1 2 Dileshni Tilakawardane 1 2 Anthony Park 1 2 Wen-Chung Chang 1 2 Sarah Wright 1 2 Christine E Brown 0 2 Stephen J Forman 0 2 0 Beckman Research Institute, City of Hope National Medical Center , Duarte, CA , USA 1 City of Hope National Medical Center , Duarte, CA , USA 2 Authors' details - Prostate Cancer (PCa) is the third most common cancer type in the United States, with over 200,000 new cases projected to be diagnosed this year. In approximately 80% of PCa patients, tumor phenotype includes overexpression of prostate stem cell antigen, or PSCA. Furthermore, PSCA is expressed on nearly 100% of bone metastatic prostate cancers, making it an attractive immunotherapeutic target. We have genetically engineered T cells to express chimeric antigen receptors (CARs) which specifically target PSCA. Recent clinical trials with CARs targeting CD19 for B-cell malignancies have demonstrated impressive results, yet replicating this success with other antigen targets remains elusive. Immunotherapy against solid tumors poses a more difficult tumor challenge because of the immunosuppressive microenvironment that can significantly hinder CAR efficacy. Additionally, there have been instances of ontarget, off-tumor toxicity due to low levels of antigen expression on normal tissue. In the current project we have modified various components of our CAR constructs to improve specificity and overall therapeutic efficacy. Through various in vitro functional assays and in vivo xenograft models, we have evaluated and optimized a PSCA-targeting CAR. We have compared two single-chain variable fragments with different paratopes, namely the A11 and the MB1 scFvs. While both show comparable potency, the MB1 scFv exhibits nonspecific activity against PSCAnegative tumor lines. Similarly, our data suggest that the 28ζ-costimulatory domain, regardless of linker length, also shows non-specific activation and killing of 1City of Hope National Medical Center, Duarte, CA, USA Full list of author information is available at the end of the article PSCA-negative tumor lines as compared to the 4-1BB costimulatory domain. Finally, we have demonstrated differences between long, middle, and short linker lengths in intracellular cytokine production, activation, and killing capacities in vitro and in vivo. By modifying both the ectodomain and intracellular region, we are able to improve the specificity and functionality of our PSCA-CARs, which is essential to developing effective immunotherapies for this advanced disease. Submit your next manuscript to BioMed Central and take full advantage of: Submit your manuscript at www.biomedcentral.com/submit (...truncated)


This is a preview of a remote PDF: http://www.immunotherapyofcancer.org/content/pdf/2051-1426-3-S2-P115.pdf

Ethan Gerdts, Saul Priceman, Dileshni Tilakawardane, Anthony Park, Wen-Chung Chang, Sarah Wright, Christine E Brown, Stephen J Forman. Development and optimization of PSCA-specific CAR T cells for the treatment of bone metastatic prostate cancer, Journal for ImmunoTherapy of Cancer, 2015, pp. P115, 3,